By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Investigators publish new report on Biotechnology. According to news reporting originating in Leiden, Netherlands, by NewsRx journalists, research stated, "The histone deacetylase inhibitors (HDACi) are a group of small molecules that target histone deacetylases (HDACs) by inhibiting their activity. HDACi have a long history of use in neurology and psychiatry as antiepileptics and mood stabilizers."
The news reporters obtained a quote from the research from Leiden University, "More recently, they have been investigated as possible treatments for cancer. HDACi have undergone rapid clinical development in recent years, on the basis of their preclinical in-vitro and in-vivo antitumor activity in hematological malignancies and solid tumors. Many HDACi have entered phase I-III clinical trials. Among the HDACi, vorinostat and romidepsin are currently the most extensively studied. In 2006 and 2009, respectively, they received approval by the United States Food and Drug Administration for treatment of cutaneous T-cell lymphoma and romidepsin for the treatment of peripheral T-cell lymphoma. Other HDACi, such as panobinostat and valproic acid, also demonstrated activity as therapeutic anticancer agents. In this article we give an overview of the clinical studies of HDACi in solid tumors."
According to the news reporters, the research concluded: "We start with a short description of the working mechanism of HDACi in general."
For more information on this research see: Histone deacetylase inhibitors: an overview of the clinical studies in solid tumors. Anti-Cancer Drugs, 2014;25(2):140-149. Anti-Cancer Drugs can be contacted at: Lippincott Williams & Wilkins, 530 Walnut St, Philadelphia, PA 19106-3621, USA. (Lippincott Williams and Wilkins - www.lww.com; Anti-Cancer Drugs - journals.lww.com/anti-cancerdrugs/pages/default.aspx)
Our news correspondents report that additional information may be obtained by contacting M. Slingerland, Leiden University, Medical Center, Dept. of Clin Pharm & Toxicol, NL-2300 RC Leiden, Netherlands. Additional authors for this research include H.J. Guchelaar and H. Gelderblom (see also Biotechnology).
Keywords for this news article include: Biotechnology, Leiden, Europe, Oncology, Treatment, Netherlands, Solid Cancers, Nucleoproteins, Amidohydrolases, Pre-Trial Research, Histone Deacetylases, Enzymes and Coenzymes, Lymphoma Gene Therapy, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC